Document is current

Any future updates will be listed below

Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review

Crossref DOI link: https://doi.org/10.1007/s12325-025-03181-z

Published Online: 2025-04-28

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark